Tips to prevent and treat blisters

Tips to prevent and treat blisters -

Whether because you have started running more or just got a new pair of sandals, it seems that summer is the blisters season. And while we often think of blisters on the feet, dermatologists say these painful skin irritations can occur anywhere on the body where the body parts rub or rub against clothing. Fortunately, they say, blisters can be avoided by preventing friction.
"Prevention is really the key when it comes to blisters," says board certified dermatologist Anthony Rossi, MD, FAAD, assistant professor of dermatology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York City. "To stop them before they appear, pay attention to your skin and take precautions if you know you'll do a lot of walking, running or other physical activity."
To avoid friction that can lead to blisters, Dr. Rossi recommends the following tips:
1.Protect your feet: To prevent blisters on your feet, wear nylon or moisture-wicking socks. If you wear a pair of socks does not work, try wearing two pairs to protect your skin. You should also make sure your shoes fit well. Shoes should not be too tight or too loose
2.Wear the right clothes :. During physical activity, wear, moisture-fitting clothes. Avoid cotton clothing, cotton absorbs sweat and moisture, which can lead to friction and friction
3.Consider flexible bandages :. For problem areas, such as the feet or thighs, consider using moleskin or other dressings flexible adhesives. Make sure the bandages are applied safely
4. Apply powder or petroleum jelly to the problems: .. This helps to reduce friction when the skin rubs together or rubbed against clothing
5. Stop your activity right away if you feel pain or discomfort, or if your skin turns red. Otherwise, you can get a blister
"If you get a blister, be patient and try to leave it alone," Rossi said. "Most of the blisters heal in only one to two weeks Do not resume the activity that caused your blister until it is healed.".
To treat blisters, Dr. Rossi recommends the following tips:
1.Cover the blister: cover the blister with a bandage Bring in the sides of the tape so that the middle of the band is a little high [
2.The padding :. to protect the bulbs in pressure areas, such as the bottom of your feet, use a stuffing. Cut the padding donut with a hole in the middle and place around the bulb. Next, cover the blister and upholstery with a bandage.
3.Avoid popping or draining a blister because this could lead to infection. However, if your blister is large and very painful, it may be necessary to drain the blister to reduce discomfort. To do this, a small needle sterilized with rubbing alcohol. Next, use the needle to carefully cut a edge of the wafer, allowing a portion of the drain fluid
4.Keep clean and covered area :. Once your blister drained, wash the area with water and soap and apply petroleum jelly. Do not remove the "roof" of the blister, as this will protect the raw skin underneath as it heals.
"As your blister heals shows signs of infection," said Rossi. "If you notice redness, pus, pain or increased swelling, make an appointment to see your doctor or a board-certified dermatologist. "

UCI molecular biologists a new way to fight against skin cancer

UCI molecular biologists a new way to fight against skin cancer -

Using immunotherapy new and innovative approaches to silence "do not eat me" signaling proteins recognized by specialized cells of the immune system, University of California, Irvine molecular biologists and their colleagues have identified an effective way to fight against metastatic melanoma.
Directed by D. Alexander Boiko, UCI molecular biology assistant professor and Biochemistry at the Ayala school bioscience and Sue and Bill Gross Stem Cell Center, the researchers found that blocking protein cell surface CD47 (known as a signal "do not eat me") on melanoma cells, increased the degree to which these cells were phagocytosed or "consumed" by macrophages. the team also discovered that blocking CD47 in combination with targeting a second cell surface protein, CD271, previously shown to be expressed on melanoma cell initiation, resulted in a virtually complete inhibition in metastases from human melanoma tumors in mice grafted the complete study appears Aug. 9 in cell reports (Link to study..: http://www.cell.com/cell-reports/fulltext/S2211-1247(16)3080-7)
The CD47 cell surface protein has been found to be overexpressed in metastatic melanomas, which allows them to avoid being eliminated by the immune system of the body. CD271, on the other hand, has been shown by Boiko previously to mark a population of cells in melanoma responsible for the initiation of the tumor and the metastatic spread this aggressive cancer. for the current study, Boiko and his team surmised that metastatic melanomas relied on the overexpression of both protein to fool the immune system and spread to other parts of the body.
to test this hypothesis, Boiko and his colleagues used specific blocking antibodies directed against CD47 (to activate macrophage phagocytosis) and CD271 (to selectively target population of more aggressive melanoma cells.) When mice bearing human metastatic melanoma were treated with this antibody regimen, researchers discovered that the simultaneous application of antibodies against CD47 and CD271 yielded the almost complete elimination of all metastases of experimental mouse organs. The group Boiko has further found that this treatment effect was mediated by a profound alteration of the microenvironment surrounding the tumor, causing immune cells to fight against cancer more effectively.
"Further research is needed to determine the anti-metastatic properties complete the double CD47 / CD271 antibody therapy and safety of its application in human patients," said Boiko. "However, the combination of this therapy with other new treatments that modulate the immune system represents a new approach that can offer increased benefits against metastatic melanoma. These are very exciting times for the field of cancer immunotherapy and we aim to add an important element to this type of treatment, which will hopefully result in a more effective outcome for patients. "

Losing weight can reduce the levels of certain proteins linked to tumor growth

Losing weight can reduce the levels of certain proteins linked to tumor growth -

Bottom Line: Women in overweight and obese people who lost weight by diet and exercise reduced levels of certain proteins in their blood that play a role in angiogenesis, the process of growth of blood vessels that can promote the growth and survival of cancer cells
Log in which the study was published :. Cancer Research , a journal of the American Association for Cancer Research
Author :. Catherine Duggan, Ph.D., Scientific Director of the staff of the Public Health Sciences Division at the Research Centre for Cancer Fred Hutchinson in Seattle, Washington
Background: Angiogenesis is a vital function when new blood vessels are formed, for example, during wound healing, Duggan explained. Unfortunately, a significant portion of tumor growth and development is dependent on a supply of blood vessels to provide nutrients and oxygen to allow a tumor to continue to grow. Some researchers have proposed that "angioprevention," that is, preventing the growth of tumor cells by preventing angiogenesis, may be an important strategy for preventing cancer in healthy people, but drugs that block this processes have potential adverse effects, which is a deterrent to use for cancer prevention, she said
How the study was done :. Duggan, senior study author Anne McTiernan, MD, Ph.D., and colleagues randomly assigned 439 obese, healthy, postmenopausal women overweight / sedentary, aged 50 to 75, to one the four arms of the study to measure the effect of exercise and diet on circulating levels of proteins associated with angiogenesis after 12 months
four arms were :. a calorie restriction diet arm in which women restricted their caloric intake to no more than 00 kcal per day which included less than 30 percent of calories from fat; an aerobic exercise arm in which women performed 45 minutes of moderate to vigorous exercise five days a week; diet + exercise combined arms; and a control arm (no response)
Blood samples were collected at the beginning and 12 months
Results: .. After adjusting the data for the index body mass, age, and race / ethnicity, the researchers found that after 12 months of intervention, on average, women in the food arm, the arm of exercise and diet + exercise arm lost 8.5, 2.4 and 10.8, percent of body weight, respectively, which was significantly higher than the average weight loss for women in the control arm (0.8 percent).
After 12 months, compared to women in the control arm, those in power arm and diet + exercise arm had significantly lower levels of proteins associated with angiogenesis, but these effects are not obvious to those of the drive arm only. The researchers also observed a linear trend in the reductions, which means that weight loss had more women, more reductions in their levels of protein related to blood angiogenesis.
The proteins studied include VEGF, PAI-1. and PEDF
Author Comment: ". We know that being overweight and having a sedentary lifestyle is associated with an increased risk of developing certain types of cancer, however, we do not know exactly why" Duggan said. "We wanted to investigate how the levels of certain biomarkers associated angiogenesis have been changed when overweight, sedentary, postmenopausal women participating in a research study lost weight and / or become physically active during a year. "
" Our study shows that weight loss is a safe and effective method to enhance the angiogenic profile in healthy individuals. We were surprised by the magnitude of change in these biomarkers with weight loss, "said Duggan.
"While we can 't say for certain that the reduction of circulating levels of angiogenic factors by the weight loss would affect tumor growth, it is possible they could be associated with a environment less conducive to tumor growth and proliferation, "noted Duggan.
"exercise is important to help prevent weight gain and maintain weight loss, but does not cause a large amount of weight loss on its own" Duggan said. "Our study shows that lifestyle changes - in this case, simple changes to diet to reduce weight. - can reduce risk factors for cancer "
Limitations: The researchers measured three angiogenic factors while there are many others. In addition, biomarkers were measured only in the circulating blood and not in the adipose tissue or other tissue, said Duggan.

Three candidate vaccines provide complete protection against the virus Zika in rhesus monkeys

Three candidate vaccines provide complete protection against the virus Zika in rhesus monkeys -

One month after announcing that two promising vaccine candidates provided mice with complete protection against the virus Zika, a research team at Beth Israel Deaconess Medical Center (BIDMC), in collaboration with scientists from the Institute of Walter Reed Army research (WRAIR) and the University of São Paulo, reports now achieve complete protection against the Zika virus in rhesus monkeys. The research team's findings were published online today in the journal Science.
This week Florida officials have confirmed that fourteen people contracted the virus Zika in Miami-Dade and Broward counties, the first known transmission by mosquitoes in the continental United States. The Centers for Disease Control and Prevention (CDC) has recommended that pregnant women avoid these areas, which is the first time in history that recommended avoiding travel to areas in the continental United States. Because Zika infection among pregnant women has been shown to lead to fetal microcephaly and other major birth defects, development of a safe vaccine is an urgent global health priority.
"Three vaccines provided complete protection against the Zika virus in non-human primates, that is the best animal model before starting clinical trials," said lead author Dan H. Barouch, MD, Ph.D., director of the Center for Virology and Vaccine Research at BIDMC, professor of medicine at Harvard medical School and member of the board at the Ragon Institute of MGH, MIT and Harvard. "The consistent and robust protection against Zika virus in rodents and primates fuels our optimism about the development of a safe and effective vaccine Zika for humans."
Vaccines work by stimulating . the immune system to develop defenses against the virus the researchers tested three means of production Zika immunity in rhesus monkeys: an inactivated virus (PIV) vaccine developed by researchers purified the army to WRAIR and a plasmid DNA vaccine and vector adenovirus-based vaccine product at BIDMC. All three platforms have proven remarkably effective, and no adverse effects were observed.
to test the PIV vaccine, scientists immunized eight monkeys rhesus with inactivated virus Zika and eight monkeys with a dummy vaccine. Within two weeks, the immune system of animals produced antibodies against the virus. After a booster four weeks, the antibody levels increased significantly. When these animals were exposed to two infectious Zika virus strains from Brazil and Puerto Rico, they showed complete protection against the virus, Zika virus without detectable in blood or other bodily secretions.
In a second experiment, 12 rhesus monkeys were immunized with either a DNA vaccine or a vaccine based on adenovirus vectors. These types of vaccines only introduce a DNA fragment Zika virus encoding the outer layer Zika virus in the body. These vaccines have led the immune system to produce antibodies. In this study, both vaccines have produced antibodies specific Zika in all primates tested with the adenoviral-based vaccine causing a wider and a more potent antibody response. When primates were exposed to the Brazilian strain of Zika, both vaccines provide complete protection. These data suggest that clinical trials for these Zika virus vaccine candidates should proceed as quickly as possible.

Research shows biglycan molecule plays a key role in determining the malignancy of the tumor

Research shows biglycan molecule plays a key role in determining the malignancy of the tumor -

Researchers from Hokkaido University in Japan have shown that a molecule called biglycan, plays an intrinsic role in attracting the tumor cells to the inner wall of the blood vessels of the tumor.
Biglycan is a normal constituent of cells outside of the support matrix and appears to modulate the biological activity of a number of growth factors. It is also released by immune cells into inflamed tissues.
The team has investigated graft-low metastatic (LM) and high metastatic (HM) melanoma tumor cells in mouse skin.
They found the "endothelial" cells forming the inner lining of blood vessels in tumors secrete HM levels of biglycan, which binds to specific receptors on tumor cells, to attract the increased endothelium. When the neutralized Biglycan receptors with antibodies, the migration of tumor cells to endothelium was inhibited.
They asked why the biglycan expression was increased in endothelial cells, and found that the gene's promoter region was de-methylated, meaning that the gene was turned on. They think that the tumor cells have created a micro-environment that could induce the expression of abnormal gene in the neighboring tissue.
The team analyzed a large database that contains gene expression data in cancer patients. They found that high biglycan expression was associated with poor prognosis in patients with breast, lung and colorectal cancer. Further on a specific case of metastatic cancer showed high levels of biglycan investigation in the blood of patients with metastatic cancer, when he was barely detected in another non-metastatic cases.
The research provides clear evidence that biglycan is important role in determining the malignancy of the tumor. endothelial cells of blood vessels act as "gatekeepers" the researchers write in their study published in the journal Scientific Reports . In highly metastatic tumors, these cells give the molecule of tumor cells "key", biglycan, which allows them to break the door and proceed into the blood stream, resulting in metastasis.
"These comments and unravel some outstanding issues can contribute to the establishment of an accurate diagnosis or potent antimetastatic strategies that target the communication between tumor cells and endothelial cells, "the researchers conclude.

New strategy addresses the fatal autoimmune disease with no outward effects off-target

New strategy addresses the fatal autoimmune disease with no outward effects off-target -

In a study that could have important implications for the future treatment of auto- immunity and related conditions, scientists at the Perelman School of Pennsylvania University of medicine found a way to remove the subset of making antibody-producing cells that cause autoimmune disease without harming the rest the immune system. The autoimmune disease of the team studied is called pemphigus vulgaris (PV), a condition in which specific immune cells from a patient attack a protein called DSG3 (Dsg3) that normally adheres the skin cells.
Current treatments of autoimmune disease, such as prednisone and rituximab, remove much of the immune system, leaving patients vulnerable to opportunistic infections and potentially deadly cancers.
The Penn researchers demonstrated their new technique in dealing successfully autoimmune disease otherwise fatal in a mouse model without apparent off-target effects, which could harm healthy tissue. The results are published in an online document First release in science.
"This is an effective strategy to target the autoimmune cells and sparing just good immune cells that protect us against infection," said co-lead author Aimee S. Payne, MD, PhD, Albert M. Kligman Associate Professor of Dermatology.
Payne and co-senior author Michael C. Milone, MD, PhD, assistant professor of pathology and laboratory medicine, adapted the technique of the strategy against the promising cancer by which cells T are designed to destroy malignant cells in certain leukemias and lymphomas.
"Our study effectively opens the application of this anti-cancer technology for the treatment of a wide wider range of diseases, including autoimmunity and transplant rejection," said Milone .
the key element of the new strategy is based on a target receptor recognizing artificial called chimeric antigen receptor, or CAR, which can be engineered into the patient's T cells. in human trials , researchers remove some of the patient's T cells by a process similar to dialysis, then engineer in a laboratory to add the CAR gene so that the new receptor is expressed in T cells the new cells are then multiplied in the . lab before re-infusion into the patient T cells use their CAR receptors to bind to molecules on the target cells, and the act of binding initiates an internal signal that strongly activates T cells -. So they quickly destroy their targets
The RCA base T cell concept was first described in the late 1980s, primarily as a strategy against cancer, but the technical challenges delayed its translation into successful therapies. Since 2011, however, the experimental CAR T cell treatments for leukemia and B cell lymphomas - cancers in which healthy B cells of patients become cancerous -. Have been successful in some patients for whom all standard treatments failed
B cells that produce antibodies, can also cause autoimmunity. Payne autoimmunity research, and a few years ago, a postdoctoral researcher in his lab, Christoph T. Ellebrecht, MD, took an interest in CAR T cell technology as a potential weapon against autoimmune diseases B cells Soon the laboratory Payne teamed with Milone, who studies CAR T cells technology, hoping to find a powerful new way to treat these conditions.
"We thought we could adapt this technology which is really good to kill all the B cells of the body to specifically target B cells that make antibodies that cause autoimmune diseases," said Milone.
"target only the cells that cause autoimmunity was the ultimate goal of therapy in this area," noted Payne.
A more specific receptor disease
in the new study, which Ellebrecht was the first author, the team aims to pemphigus vulgaris. This condition occurs when antibodies from a patient attack the molecules that normally prevent cells skin together. When untreated, PV led to extensive blistering of the skin and is almost always fatal, but in recent decades, the condition was treatable with broadly immunosuppressive drugs such as prednisone, mycophenolate mofetil and rituximab.
To treat PV without causing broad immunosuppression, the Penn team designed an artificial RCA receiver who would lead the patient's T cells to attack only the harmful B cells producing anti-Dsg3 antibodies.
the team developed a "chimeric receptor autoantibody," or SRL, which shows fragments of Dsg3 of autoantigen - the same fragments for which PV causing antibodies and B cells generally bind in as laboratory and other Payne demonstrated in previous studies. Acts of artificial receptors as a decoy for B cells that target Dsg3, putting them in touch with fatal therapeutic T cells.
many variations Test, the team finally found an artificial receptor design worked well in cell culture, enabling T cells to effectively destroy host cells producing antibodies to Desmoglein, including from PV patients. The modified T cells also successfully performed in a murine model of PV, kill specific cells Desmoglein B and preventing the formation of blisters and other manifestations of autoimmunity in animals.
"We were able to demonstrate that the treatment killed all Dsg3 specific B cells, a proof of concept that this approach works," said Payne.
T cell therapies can be complicated by many factors. But, in these experiments, the cells modified by the Penn scientists have retained their activity despite the presence of anti-Dsg3 antibodies that have spread their artificial receptors. Furthermore, there was no sign that the modified T cells caused side effects by hitting the wrong target cell in mice.
The team now plans to test their treatment in dogs, which can also develop PV and often die of the disease. "If we can use this technology to cure PV safely in dogs, it would be a breakthrough for veterinary medicine, and would hopefully pave the way for trials of this therapy in humans pemphigus patients," said Payne .
Also on the horizon for the Penn scientists are applications SRL T-cell technology to other types of autoimmunity. Immune rejection complicating organ transplants, and normally requires immunosuppressive therapy long-term medication, may also be treated with cellular technology T. SRL
"If you can identify a specific marker of B cell that you want to target, then, in principle, this strategy can work, "said Payne.

Mutations in genes STN1 cause Coats, plus

Mutations in genes STN1 cause Coats, plus - syndrome

A team of Israeli researchers has discovered that mutations in STN1, a gene that helps maintain the ends of chromosomes, cause rare, inherited disorder and Coats syndrome. The study "mutations cause Coats STN1 and the syndrome and are associated with genomic defects and telomeres," will be published online before publication in July 18 The Journal of Experimental Medicine .
and Coats syndrome affects many body tissues, including the eye, brain, bone marrow and the gastrointestinal tract. the disease is a telomeropathy known to be caused by mutations in the gene encoding CTC1, a protein that helps maintain telomere structures called that protect the ends of chromosomes. If the telomeres are not maintained properly, the cells lose their ability to divide and chromosomes can fuse together.
Directed by Gideon Raz Somech Rechavi and Central and Sara Sheba medical Selig Rambam Health Care Campus and the Technion Institute, the researchers identified two Palestinian Coats and patients who do not have mutations in the gene CTC1. Instead, patients carried mutations in the gene encoding STN1, a protein that functions in conjunction with CTC1 and another protein, Ten1 to maintain telomeres. Cells isolated from patients had dysfunctional telomere and a decreased ability to divide.
To confirm that mutations in STN1 were the cause of the coats and the patients' symptoms, the researchers, in collaboration with David Wiest of the Fox Chase Cancer Center, has knocked out the equivalent gene in fish embryos zebra. The coats of most developed fish-like symptoms engineering, including a lack of red blood cells and the formation of expansion, fragmented blood vessels. This last symptom has been corrected using thalidomide, a potent inhibitor of blood vessel formation.
The researchers report that one of the two patients died as a result of massive gastrointestinal bleeding. However, they were able to partially control the gastrointestinal bleeding of the second patient using thalidomide, which shows a success "approach to bed bed-and-back." The researchers now plan to study exactly how mutations in STN1 cause patient symptoms. In addition to maintaining telomeres, the protein complex of DNA replication CTC1-STN1-Ten1 auxiliaries on the whole genome, a process that is also defective in cells of patients. "How many features can be attributed to telomere or genome-wide replication defects, or other non-replicating DNA defects are still exploring," the researchers say.

Researchers find human factor that causes the maturation of T helper

Researchers find human factor that causes the maturation of T helper -

A powerful arm of the immune system is the production of antibodies that circulate in the blood and neutralize pathogens invaders. Although B cells actually produce antibody protein, the process is aided by neighboring T cells, including B cells with shower cytokines to make them churn out antibodies of high quality protein - and remember how make. Given the essential role of T cells "helper", researchers have long sought to define the biological signals that promote their development. So far, the best candidates were only minor effects on human immune cells.
Now, an article published by La Jolla Institute (LJI) researchers in the July 2016 issue Nature Immunology identifies a human factor that causes the maturation of T helper cells called helper T cells follicular (TFH) cells. This factor, a cytokine known as activin A, specifically entails maturation of human Tfhs and different factors which act similarly in mice. This work, conducted LJI biologist vaccine Shane Crotty, Ph.D., fills a gap in knowledge by revealing signals that could be therapeutically targeted either stimulate immune responses to fight against the infection or to slow down, in the case of a autoimmune disease.
"most human vaccines work by inducing an antibody response. For these responses are of high quality you need for TFH cells," says Crotty, professor in the division of LJI discovery of a vaccine. "Our study has identified an unexpected signaling protein that is very good to induce the maturation of human TFH cells. Knowing this could help us learn how to design more potent vaccines."
One reason for achieving the objective has been difficult is that previously, many research laboratories, including Crotty, had conducted experiments on mouse models and found that the key factors Tfh of differentiation in rodents differed from those governing human immune cells. Thus, focusing on human factors alone, Crotty laboratory set up an impartial search 2,000 candidate proteins, automated strategy called "high-throughput screening."
Specifically, their task was to comb through a collection or "library" of candidates signaling molecules and testing them one by one to see if anyone could stimulate maturation of immature human TFH cells cultured. the best candidate out of the screen is a secreted protein called activin a member of the family of cytokines.
followed by experiments confirmed that exposure to activin a stimulated immature TFH cells to express genes encoding receptors and other factors typical in mature cells, while the fluorescence microscopy revealed activin a protein in tonsil lymphoid tissues near sites Tfh differentiation has taken place and in close proximity with the cell B. This circumstantial evidence has demonstrated that activin a has was produced in the "right place".
Other comparisons explored and confirmed the rodent / human divergence that had proven to be such an obstacle. The incubation of immature mouse T cells with activin A did not actually encourage their maturation, while the treatment of immature Tfhs macaque monkeys with activin A did.
The discovery of a single primate mechanism is intriguing from an evolutionary point of view, as the biochemical pathways regulating immune activities are often highly conserved in mammals. "Mice are extremely useful in biomedical research in helping us to understand how genes and proteins function," says Crotty. "But from time to time, we see the differences between species, and cell differentiation Tfh was one of those case. "
Finally, the team showed that for activin a boost Tfh maturation, it must activate the DNA-binding molecules called downstream SMAD2 / 3. They discovered this by treating immature TFH cells with the drug Galunisertib, which mutes the SMAD2 signaling, and found that the cells became refractory to activin signals. this experiment not only defined a biochemical pathway, but means that a medicament exists for potentially block T cell "help" keeping the TFH cells in an immature state. - the most obvious application is an autoimmune disease
"Many autoimmune diseases exhibit excessive production of TFH cells, which can lead to the formation of autoreactive antibodies, "explains Michela Locci, Ph.D., lead author of the study and a postdoctoral fellow in the laboratory Crotty. "In at least two of them - the rheumatoid arthritis and systemic lupus erythematosus -. The level of activin A in the blood is higher than normal, suggesting that it contributes to the differentiation Tfh deregulated in these diseases "Locci found these promising associations, but warns that it is too early to say whether Galunisertib, being tested as an anti-cancer drug in clinical trials, could normalize Tfh excess activity in the autoimmune disease.
Overall, the predominant interest Crotty laboratory is in the antibody-based immunity regarding vaccine development. One way that vaccines work is establishing cells B long-term memory when exposed to a recall of deadly pathogen they saw the invader before (albeit in a form of harmless vaccine) and are willing to do antibodies. When TFH cells were discovered in 01, scientists quickly realized that they were necessary for both the development of these memory B cells and instruct them on how to make high affinity antibodies.
"Generating more TFH cells could promote cell more powerful B responses and increase the production of long-term memory cells," says Crotty. "From the standpoint of the design of the vaccine, it may be desirable encourage the development of Tfh cells in vivo since the production of a protective vaccine requires the production of antibodies. "Knowing that activin a is the main source of" encouragement "could lead his laboratory to a new research, this both small molecules potentially useful for transforming activin A on the time of vaccination, instilling more lasting memories in B cells

A new study reports significant increase in new cases of prostate cancer metastatic

A new study reports significant increase in new cases of prostate cancer metastatic -

The number of new cases of metastatic prostate cancer rose 72 percent in the last decade 04-2013, reports a new study Northwestern Medicine. The report examines whether a recent trend of fewer men being screened can contribute to the rise, or if the disease became more aggressive -. Or both
The largest increase of new cases was among men 55 to 69 years, which increased 92 percent in the last decade. This increase is particularly troubling, the authors said, because men in this age group are expected to benefit most from screening for prostate cancer and early treatment.
In addition, the average PSA (prostate specific antigen) of men who have been diagnosed with metastatic prostate cancer in 2013 was 49, almost double that of men diagnosed in 04 with an average PSA 25, which indicates a greater extent of the disease at diagnosis.
The blood PSA level, a protein produced by cells of the prostate gland, is often higher in men with prostate cancer.
"One hypothesis is the disease became more aggressive, regardless of the screening change," said lead study author Dr. Edward Schaeffer, chair of urology at Northwestern University Feinberg School of Medicine and Northwestern Medicine. "the other idea is for screening guidelines have become more lax when men did diagnosed, it is at a more advanced stage of the disease. Probably both are true. We do not know for sure, but this is the subject of our current work. "
Schaeffer is also a member of the Lurie Comprehensive Cancer Center Robert H. Northwestern University.
document will be published July 19 in Prostate cancer and prostatic diseases , a journal of nature.
Schaeffer's research team analyzed information from the national database on cancer. It included 1,089 men 767.550 installations throughout the country who received diagnosed with prostate cancer between 04 and 2013.
during the last decade, there has been a substantial reduction in the number of men being prostate cancer screening and an associated decline total number of new cases of prostate cancer are reported.
"the fact that men in 2013 who had metastatic had PSA disease much higher than similar men in 04 suggests that more aggressive disease is on the rise, "said Schaeffer. "If I were a patient, I want to be careful. I firmly believe that PSA screening and rectal exams save lives."
If a patient is diagnosed with localized prostate cancer that is aggressive, treatment can be curative. If men have a metastatic prostate cancer, the treatments are not curative and only slow disease progression. Most patients with metastatic prostate cancer eventually die of the disease.
"There could be a significant increase in prostate cancer mortality rate if more people are diagnosed with metastatic disease, because treatments can slow the progression, it is not curable," said Schaeffer.
the study measured the number of cases of metastatic prostate cancer, not the effect, for example, cases per 100,000. in addition, metastatic disease began to increase in 08 before the change screening recommendations Preventive Services Task Force of the United States. Thus, investigators said, they can not definitively link the increase in cases of reduced screening alone.
Three percent those included in the study had metastases, which means that cancerous prostate cells had spread to other parts of their bodies by the time the cancer was diagnosed. the number of cases of metastatic prostate in 2013 (280) was 72 percent higher than in 04 (1,685). In middle-aged men 55 to 69 years, the number increased by 92 percent from 702 new cases in 04 to 1345 in 2013.
"The results indicate that the guidelines and the treatment screening must be refined based on each patient's risk factors and genetics, "said lead author Dr. Adam Weiner, a urology resident Feinberg. "This can help prevent the increasing occurrence of metastatic prostate cancer and potential death associated with the disease. This can also help reduce overdiagnosis and overtreating men with prostate cancer at low risk who do not require treatment."
"This will be especially critical for the economy of the health population in the United States, given the additional cost of care for metastatic prostate and an aging constituency whose population aged over 65 will double to over a projected 80 million by 2050, "Schaeffer said.

The European Commission approved an expanded indication for Kyprolis Amgen (of carfilzomib) for the treatment of patients with multiple myeloma relapse

The European Commission approved an expanded indication for Kyprolis Amgen (of carfilzomib) for the treatment of patients with multiple myeloma relapse -

Amgen announced that the European Commission (EC) approved a variation of the marketing authorization for Kyprolis® (carfilzomib) to include the use in combination with dexamethasone alone for patients with multiple myeloma adults who received at least one prior therapy. Prolonged marks the second indication for Kyprolis approval by the EC in less than a year.
"In the Phase 3 head-to-head, Kyprolis in combination with dexamethasone doubled the time patients lived without their cancer progressing and the complete response rate compared to bortezomib and dexamethasone, "said Sean E. Harper, MD, executive vice president of research and development at Amgen." Kyprolis based schemes have shown the superiority of two old options of therapeutic standard of care for patients relapsed myeloma, strengthening Kyprolis place as a fundamental therapy in this patient population. "
The EC approved the expanded indication for Kyprolis based on data from the Phase 3 head-to-head ENDEAVOR in which multiple myeloma patients treated with Kyprolis plus dexamethasone (Kd) with superior progression free survival (PFS) of 18.7 months against 9.4 months in those receiving bortezomib plus dexamethasone (Vd) (HR = 0.53; 95 percent CI: 0.44, 0.65; p <0 .0001="" 6.2="" against="" also="" better="" compared="" complete="" demonstrated="" double="" em="" endpoints="" for="" improvement="" in="" including="" kd="" on="" or="" patients="" percent="" rate="" response="" secondary="" the="" those="" to="" treated="" vd="" were="" which="" with=""> p

<0 .0001="" 20="" 28="" 2="" 32="" 36="" 4="" 8="" a="" adverse="" and="" anemia="" bortezomib="" both="" but="" ci:="" common="" cough="" diarrhea="" dose-limiting="" dyspnea="" edema.="" events="" experienced="" fatigue="" frequent="" grade="" groups="" higher="" in="" infection="" kd="" kyprolis="" lower="" most="" nausea="" neuropathy="" occurred="" of="" or="" p="" patients="" percent="" peripheral="" profile="" pyrexia="" rate="" reactions="" receiving="" respectively="" respiratory="" safety="" significantly="" similar="" than="" that="" the="" those="" thrombocytopenia="" toxicity="" tract="" treated="" vd="" vs.="" was="" were="" with="">
Kyprolis was first approved by the EC in November 2015 for use in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy based on results of the ASPIRE study. Today's approval by the EC following the approval of the US Food and Drug Administration of a New Drug Application extra based on the results of ENDEAVOR in January 2016.
Multiple myeloma is an incurable blood cancer characterized by a recurring pattern of remission and relapse.1 It is a rare and very aggressive disease that represents approximately one percent of all cancers worldwide.2-4 in Europe, approximately 39,000 patients are diagnosed with multiple myeloma each year and 24,000 patient deaths are reported annually basis.5
about ENDEAVOR
The randomized ENDEAVOR (Randomiz E d, Ope N label, phase 3 study carfilzomib more dE xameth A sone V s bortezomib more Dexamethas O not in patients R elapsed multiple myeloma) trial of 929 patients evaluated Kyprolis in combination with low-dose dexamethasone, versus bortezomib with low-dose dexamethasone in patients with myeloma multiple relapsed after at least one but no more than three prior therapies. The primary outcome of the trial endpoint was PFS, defined as the time between the start of treatment until disease progression or death. In a clinical trial, the measurement of the PFS is a way to demonstrate how a works.6 treatment
As noted above, Kyprolis with dexamethasone (Kd) was superior to bortezomib and dexamethasone (Vd) and demonstrated much longer PFS. Improvement in PFS in the Kd arm relative to Vd arm was seen through the pre-specified key subgroups including patients naive bortezomib those cytogenetic high or standard risk and with or without prior transplantation .
In terms of secondary endpoints, Kd achieved an overall response rate higher than Vd (76.9 percent against 62.6 percent; p <0 .0001="" 28.6="" 54.3="" a="" achieved="" and="" better="" bortezomib="" em="" good="" group="" in="" kyprolis="" of="" or="" partial="" patients="" percent="" response="" very=""> p
<0 .0001="" and="" are="" be="" continue="" data="" mature="" monitored.="" not="" overall="" p="" respectively.="" survival="" to="" yet=""> Discontinuation due to adverse events and deaths on the study were comparable between the two arms.7 A number of adverse reactions to known drugs were reported at a higher rate Kyprolis in the bortezomib group compared to the group, including any grade dyspnea, hypertension, pyrexia, and cough as were all grades of heart failure (group term; 8 percent against 3 percent) and acute renal failure (group term; 8 percent against 5 percent) .7
adverse event rate of 3 or higher degree were 73 percent in the Kyprolis group and 67 percent in the group7 bortezomib adverse events higher interest in Kyprolis and grade 3 or bortezomib groups included hypertension (preferred term, 9 percent against 3 percent), dyspnea (preferred term; 5 percent against 2 percent), heart failure (group term; 5 per cent against 2 per cent), acute renal failure (group term; 4 percent against 3 percent), ischemic heart disease (group term; 2 per cent against 2 per cent) and pulmonary arterial hypertension ( grouped term, 0.6 percent against 0.2 percent) .7
patients received treatment until progression with Kyprolis in 30-minute infusion on days 1, 2, 8, 9 , 15 and 16 of a 28 day treatment cycle. Patients received low-dose dexamethasone (20 mg) orally or intravenously on days 1, 2, 8, 9, 15, 16, 22 and 23 of each treatment cycle. For cycle 1 only, Kyprolis was administered at 20 mg / m2 day 1 and 2, and if tolerated followed by escalation to 56 mg / m2 on day 8. Patients who tolerated 56 mg / m2 cycle 1 were maintained at this dose for subsequent cycles. Patients who received bortezomib (1.3 mg / m2) with low-dose dexamethasone (20 mg) were administered subcutaneous or intravenous bortezomib at the discretion of the investigator and in accordance with regulatory approval of bortezomib. Over 75 percent of patients in the control arm received bortezomib subcutaneously. This study was conducted in 235 sites worldwide. For more information about this trial, please visit www.clinicaltrials.gov under trial identification number NCT01568866.
About Kyprolis® (carfilzomib)
proteasomes play an important role in cell function and growth by breaking down proteins that are damaged or more needed .8 Kyprolis has been shown to block proteasome, leading to an excessive accumulation of proteins in cells.8 in some cells Kyprolis can cause cell death, particularly in myeloma cells because they are more likely to contain greater proteins.8,9 abnormal amount of
Kyprolis is approved in the US for the following:

• in combination with dexamethasone or lenalidomide plus dexamethasone for the treatment of patients multiple myeloma relapsed or refractory who received a three-line treatment.
• as a single agent for the treatment of multiple myeloma patients with relapsed or refractory who received one or more lines of therapy.

Kyprolis is also approved in Argentina, Israel, Kuwait, Mexico, Thailand, Colombia, Korea, Canada, Switzerland, Russia, Brazil and the European Union. Additional regulatory applications for Kyprolis are ongoing and have been submitted to health authorities worldwide.
For more information on the United States, please visit www.kyprolis.com.
Important EU Product Safety Information
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Kyprolis treatment should be supervised by a physician experienced in the use of anticancer therapy. The most serious side effects that may occur during treatment Kyprolis include: cardiac toxicity, pulmonary toxicity, pulmonary hypertension, dyspnea, hypertension, including hypertensive crisis, acute renal failure, lysis syndrome tumor, reactions infusion, thrombocytopenia, hepatic toxicity, posterior reversible encephalopathy syndrome (PRES) and thrombotic thrombocytopenic purpura / hemolytic uremic syndrome (TTP / HUS). The most common side effects are anemia, fatigue, diarrhea, thrombocytopenia, nausea, pyrexia, dyspnea, respiratory tract infection, cough and peripheral edema.
Please refer to the Summary of Product Characteristics for a full European Prescribing Information.
Important US Safety Information
cardiac toxicities

• The emergence or worsening of pre- existing heart failure (such as congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, myocardial infarction, including deaths after KYPROLIS administration. Some events occurred in patients whose ventricular function normal basis. Death due to cardiac arrest has occurred within a day of KYPROLIS administration.
• Monitor patients for signs or symptoms of heart or clinical ischemic heart failure. quickly assess if cardiac toxicity is suspected. Abstention KYPROLIS 4 adverse cardiac events until grade 3 or recovery, and restart KYPROLIS consider the reduction in the level 1 of the dose based on a benefit / risk assessment.
• While adequate hydration is necessary before each dose cycle 1, monitor all patients for volume overload of signs, particularly in patients at risk of heart failure. Adjust total fluid intake in clinical status in patients with a baseline heart failure or who are at risk of heart failure.
• Patients ≥ 75 years, the risk of heart failure increases. Patients with New York Heart Association Class III and IV heart failure, recent myocardial infarction, conduction abnormalities, angina or arrhythmia may be at increased risk of cardiac complications and should have a medical evaluation complete (including blood pressure and fluid management) before starting treatment with KYPROLIS and remain under close monitoring.

acute renal failure

• cases of acute renal failure and renal failure adverse events (including renal failure) were observed in patients receiving KYPROLIS. Acute renal failure have been reported more frequently in patients with advanced relapsed and refractory multiple myeloma who received monotherapy KYPROLIS. Monitor renal function with regular measurement of serum creatinine and / or creatinine clearance estimated. Reduce or hold the dose as appropriate.

Tumor lysis syndrome

• Cases of tumor Lysis Syndrome (TLS), including fatal outcome, have occurred in patients receiving KYPROLIS. Multiple myeloma and a high tumor burden should be considered a higher risk for TLS. Adequate hydration is necessary before each dose at cycle 1, and in subsequent cycles as needed. Consider uric acid lowering drugs in patients at risk of TLS. Monitor TLS evidence during treatment and manage quickly. Abstention KYPROLIS up TLS is solved.

Pulmonary toxicity

• Distress Acute Respiratory Syndrome (ARDS), acute respiratory failure, and acute pulmonary infiltrative diffuse disease like pneumonia and interstitial lung disease occurred in patients receiving KYPROLIS. Some events have been fatal. If pulmonary toxicity induced by medication, stop KYPROLIS.

Pulmonary hypertension

• Pulmonary arterial hypertension (PAH) has been reported in patients treated with KYPROLIS. To assess cardiac imaging and / or other tests as indicated. Abstention KYPROLIS for PAH until resolved or returned to baseline and consider restarting KYPROLIS based on a benefit / risk assessment.

Dyspnea

• Dyspnea was reported in patients treated with KYPROLIS. Evaluate dyspnea exclude cardiopulmonary conditions, including heart failure and pulmonary syndromes. Stop KYPROLIS for grade 3 or 4 dyspnea until resolved or returned to baseline. Consider whether to restart KYPROLIS based on a benefit / risk assessment.

Hypertension

• Hypertension, including hypertensive crisis and hypertensive emergency, was observed with KYPROLIS. Some of these events have been fatal. regularly monitor blood pressure in all patients. If hypertension can not be adequately controlled, retain and assess KYPROLIS. Consider whether to restart KYPROLIS based on a benefit / risk assessment.

venous thrombosis

• venous thromboembolic events (including deep vein thrombosis and pulmonary embolism) were observed with KYPROLIS. VTE prophylaxis is recommended for patients treated with the combination of KYPROLIS with dexamethasone or lenalidomide plus dexamethasone. The thromboprophylaxis regimen should be based on an evaluation of the underlying risks of the patient.
• Patients using oral contraceptives or hormonal contraceptive method associated with a risk of thrombosis should consider another method of effective contraception during treatment with KYPROLIS in combination with dexamethasone or lenalidomide associated with dexamethasone .

infusion reactions

• infusion reactions, including life-threatening reactions have occurred in patients receiving KYPROLIS. Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina. These reactions can occur immediately following or up to 24 hours after administration of KYPROLIS. Premedication with dexamethasone to reduce the incidence and severity of infusion reactions. Inform patients of the risks and symptoms of infusion reactions and contact immediately if they occur a doctor.

thrombocytopenia

• KYPROLIS causes thrombocytopenia with platelet recovery basis usually have the beginning of the next cycle. Thrombocytopenia has been reported in patients receiving KYPROLIS. Monitor platelet counts frequently during treatment with KYPROLIS. Reduce or hold the dose as appropriate.

liver failure and liver toxicity

• Cases of hepatic failure, including fatal cases, have been reported during treatment with KYPROLIS. KYPROLIS may cause an increase in serum transaminases. Monitor liver enzymes regularly regardless of the reference values. Reduce or hold the dose as appropriate.

thrombotic microangiopathy

• Cases of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura / hemolytic uremic syndrome (TTP / HUS), including the fatal outcome occurred in patients receiving KYPROLIS. Monitor for signs and symptoms of TTP / HUS. KYPROLIS stop if the diagnosis is suspected. If the diagnosis of TTP / HUS is excluded KYPROLIS can be restarted. The safety of resuming KYPROLIS therapy in previously challenging TTP / HUS patients is not known.

Syndrome posterior reversible encephalopathy (PRES)

• Cases of PRES have occurred in patients receiving KYPROLIS. NEAR was formerly known as reversible posterior leukoencephalopathy syndrome. Consider a neuro-radiological imaging (MRI) for the appearance of visual or neurological symptoms. KYPROLIS stop if PRES is suspected and evaluated. The safety of resuming KYPROLIS treatment in patients previously SEPR experience is not known.

Toxicity embryofoetal

• KYPROLIS may cause fetal harm when administered to a pregnant woman based on its mechanism of action and results in animals.
• Females of reproductive potential should be advised to avoid becoming pregnant during treatment with KYPROLIS. The males of reproductive potential should be advised to avoid fathering a child during treatment with KYPROLIS. If this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the patient should be informed of the potential hazard to the fetus.

ADVERSE REACTIONS

• The most common adverse reactions occurring in at least 20% of patients treated with KYPROLIS in trials of combination therapy: anemia, neutropenia, diarrhea, dyspnea, fatigue, thrombocytopenia, pyrexia, insomnia, muscle spasms, cough, upper. respiratory infection, hypokalemia

The most common adverse reactions occurring in at least 20% of patients treated with KYPROLIS in monotherapy trials: anemia, fatigue, thrombocytopenia, nausea, pyrexia , dyspnea, diarrhea, headache, cough, peripheral edema.
full prescribing information for the United States is available www.kyprolis.com.
about Amgen
Amgen is committed to unlocking the potential of biology for patients with severe disease by discovering, developing, manufacturing and delivery of innovative human therapeutics. This approach begins by using tools such as advanced human genetics to unravel the complexities of the disease and to understand the basis of human biology.
Amgen focuses on areas of unmet medical needs and uses its expertise to work for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to become a leading independent biotech companies in the world, has reached millions of patients worldwide and develops a drug pipeline with a potential breakaway. < br />